Tilray Brands, Inc. - Common Stock (TLRY)

Tilray shares edged higher in premarket trading after the company rebranded its Italy unit as Tilray Medical Italia and highlighted expansion plans in the regulated medical cannabis market.

The company's international cannabis sales soared by 36%, and it cut its losses in half.

One strong quarter hardly makes up for the past few years.

As of January 9, 2026, the cannabis sector finds itself at a historic crossroads, caught between the euphoria of federal progress and the harsh reality of market mechanics. Following a landmark Executive Order in late 2025 aimed at accelerating the rescheduling of marijuana, the industry has entered the new year

Alliance Global cut TLRY’s target price to $10 from $20, citing limited visibility into the company’s long-term sales trajectory and cash flow.

Tilray Brands, Inc. (NASDAQ:TLRY) shares are trading higher after the company reported better-than-expected second quarter financial results.

U.S. stock futures pared earlier losses to advance on Friday after a mixed Thursday. Futures of major benchmark indices were trading higher.

Tilray had good things to say about its recent quarter -- and investors were listening.

Here's a detailed look inside the Q2 earnings report from Tilray Brands.

Tilray shares are flat Thursday morning as the company prepares to report its fiscal second-quarter 2026 results after the bell, stirring investor interest.

As Canadian cannabis king Tilray prepares to report its fiscal Q2 results on Thursday, the company stands at a crossroads.

Tilray's stock price has been highly volatile in the past few months.

This week's earnings calendar features a mix of early reports in the cannabis, AI infrastructure and consumer goods sectors.

Don't press the buy button just yet.

The marijuana business just got a little easier in America -- and maybe a whole lot more profitable.

Date: 12/15/2025 1. Introduction Tilray Brands, Inc. (NASDAQ: TLRY) is a diversified global lifestyle consumer packaged goods (CPG) company operating at the dynamic intersection of the cannabis, alcoholic beverage, and wellness industries. Headquartered in New York City, Tilray boasts a significant operational footprint across Canada, the United States, Europe, Australia, New Zealand, and Latin America, [...]

Is it too late to jump on the bandwagon?

President Donald Trump just signed an executive order that reclassified marijuana from a Schedule I narcotic to Schedule III.

These cannabis companies could soon see more green thanks to the president's milestone decision.